Patients & Care Partners

Welcome to Agenus.

We are committed to supporting you throughout your journey to conquer cancer.

We understand that receiving a cancer diagnosis can be overwhelming and filled with uncertainties. That’s why we are here to share knowledge, including providing you with information about our groundbreaking advancements in immunotherapy that have the potential to revolutionize cancer treatment.

At Agenus, the way we work sets us apart. Our core values unite us, and we put the patient first. We aspire to change the world by improving the experience and options available to every single cancer patient.

About Immunotherapy

Immunotherapy represents a new era in oncology, harnessing the power of the body’s immune system to recognize and combat cancer cells. It has emerged as a transformative approach that offers new possibilities and improved outcomes for patients across various cancer types.

Novel Immunotherapy Combination: botensilimab (BOT) + balstilimab (BAL)

Botensilimab (BOT)

is known as a CTLA-4 inhibitor. It primes, activates, and recruits cancer fighting cells.

Balstilimab (BAL)

is known as a PD-1 inhibitor. Its job is to remove a tumor’s defenses that evade and suppress the immune system.

When used together, BOT + BAL is a novel immunotherapy combination that has shown promise in treating “cold” tumors.

Cold tumors are hard for your immune system to see, so they are harder to treat. BOT and BAL were specifically designed to harness the power of your immune system to recognize and destroy your cancer cells in multiple ways:

Activates Immune System

Stimulates existing immune cells to more effectively recognize and attack cancer

Boosts Immune Response

Primes and expands new immune cells that recognize and kill cancer

Reduces Immune Suppression

Removes regulatory immune cells that suppress the immmune response


Establishes “memory” immune cells to combat future cancers

Learn more about Botensilimab

Clinical Trials

Current Clinical Research

Access to Investigational Medicines


For more information: